GlobeNewswire Inc.··Jade Biosciences, Inc.Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts
Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials